Ankit Kansagra, Medical Oncologist and Associate Vice President of Oncology Integration & Community Alignment at TGH Cancer Institute, shared on LinkedIn:
“Every BCMA bispecific on the market was approved on a response rate from fewer than 120 single-arm patients.
Etentamig just read out a 393-patient randomized Phase 3 – both primary endpoints met – before any approval at all.
That’s the harder road, and credit is due: to the CERVINO investigators, the patients who enrolled, and AbbVie for choosing to generate the evidence this field needs.
I wrote up why this matters for where myeloma drug approval is headed ”